NTN1中和劑與抑制後生控制之藥物之組合治療农业专利-农业学术服务平台

发明人:: GRANDIN, MELODIE,格兰登　美乐蒂,格蘭登　美樂蒂,DANTE, ROBERT,丹提　罗伯特,丹提　羅伯特,MEHLEN, PATRICK,梅伦　派翠克,梅倫　派翠克,DEPIL, STEPHANE,第波　史蒂芬妮,GUYON, JORDAN,古杨　乔登,古楊　喬登,格兰登美乐蒂,格蘭登美樂蒂,丹提罗伯特,丹提羅伯特,梅伦派翠克,梅倫派翠克,第波史蒂芬妮,古杨乔登,古楊喬登

摘要：: The pharmaceutical or anticancerous composition is useful in treating a cancer having a DNA methylation dependent loss of expression of NTN1, UNC5H or DAPK1. The invention also relates to a method of treatment of such cancers. The composition comprises an epigenetic drug and a NTN1 neutralizing agent or a vector capable of expressing a NTN1 neutralizing agent in vivo, in a pharmaceutically acceptable carrier or vehicle. The NTN1 neutralizing agent, such as an antibody binding to netrin-1 or to a netrin-1 receptor, promotes netrin-1 receptors-induced apoptosis. The epigenetic drug may be a DNA methyltransferase inhibitor or an HDAC inhibitor.本發明係關於一種醫藥或抗癌組合物，其可用於治療具有NTN1、UNC5H或DAPK1之表現之DNA甲基化依賴性損失之癌症。本發明亦關於一種治療此等癌症之方法。該組合物包含後生藥物及NTN1中和劑或能夠活體內表現NTN1中和劑之載體，其等係含在醫藥上可接受之載劑或媒劑中。該NTN1中和劑(諸如，與軸突導向因子-1或軸突導向因子-1受體結合之抗體)促進軸突導向因子-1受體誘導之細胞凋亡。該後生藥物可為DNA甲基轉移酶抑制劑或HDAC抑制劑。